What Asciminib does

Asciminib (Asciminib) is an allosteric inhibitor of BCR-ABL1 tyrosine kinase. 6 It binds to the myristoyl pocket of the ABL1 portion of the fusion protein and locks it in an inactive conformation, thereby preventing its oncogenic activity. In most patients with chronic myelogenous leukemia (CML), disease progression is primarily caused by a translocation of the Philadelphia chromosome that creates the oncogenic fusion gene BCR-ABL1 between the BCR and ABL1 genes. This fusion gene produces a synthetic fusion protein, BCR-abl 1, which exhibits elevated tyrosine kinase and transforming activity that promotes the proliferation of chronic myelogenous leukemia.